Litcius/Paper detail

All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation

Xiaoxiao Guo, Zhenhu Guo, Jingsong Lu, Wensheng Xie, Qiuzi Zhong, Xiaodan Sun, Xiumei Wang, Jianye Wang, Ming Liu, Ling-yun Zhao

2021Nanoscale19 citationsDOI

Abstract

investigations confirmed the as-synthesized NPs as an effective nano-radiosensitizer with ideal safety. More importantly, all moieties within the present nanosystem have been approved by FDA for the purpose of PCa treatment, thus making it highly attractive for clinical translation.

Topics & Concepts

RadiosensitizerCancer researchProstate cancerCell cycle checkpointIn vivoDNA damageCell cycleChemistryReactive oxygen speciesApoptosisRadiation therapyBiophysicsCancerMedicineDNABiochemistryBiologyInternal medicineBiotechnologyNanoplatforms for cancer theranosticsRadiation Therapy and DosimetryNanoparticle-Based Drug Delivery
All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation | Litcius